Biotechnology ETFs Rally on Sarepta FDA Drug Approval
September 19, 2016 at 16:09 PM EDT
Sarepta Therapeutics (NasdaqGS: SRPT) surged Monday and lifted biotechnology-related exchange traded funds after the Food and Drug Administration approved the Duchenne muscular dystrophy drug eteplirsen. Leading the charge in the ETF space on Monday, the BioShares Biotechnology Clinical Trials Fund...